BGI Genomics recently announced that its NIFTY® Non‑invasive Prenatal Testing (NIPT) product has obtained the CE-IVDR Certificate from TÜV SÜD Product Service GmbH (a leading global Notified Body designated under the IVDR).

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note.

Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, today announced multiple U.S. Food and Drug Administration (FDA) 510(k) clearances that strengthen its connected clinical digital pathology portfolio, including the industry's first standalone, AI-assisted quality control software. These advancements are designed to help pathology laboratories deliver high-quality digital images more consistently and efficiently to support timely, confident diagnoses for patients at a critical moment when case volumes, staffing pressures, and diagnostic complexity continue to increase.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the completion of Olink Explore HT proteomic analysis of approximately 5,500 research samples from The Michael J. Fox Foundation’s (MJFF) landmark study, the Parkinson’s Precision Medicine Initiative (PPMI). The resulting data are now in PPMI’s data repository, where they are available to the global research community.

Produced by Mindray, it can detect all routine physical and chemical items in urine and provide complete urine dry chemical analysis. The instrument has advantages of compact structure and simple operation.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapies.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has submitted a Dual 510(k) premarket notification, with a concurrent CLIA Waiver by Application, to the U.S. Food and Drug Administration ("FDA") for the Co-Dx™ PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro® instrument*. The submission follows the Company's previously announced completion of the clinical and analytical performance studies supporting the test.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2026.